BioSpace News Archive

Viatris Inc., a global pharmaceutical company, announced that it has been named to Forbes’ list of World’s Best Employers 2022.

Chameleon Biosciences Inc., a biotechnology company focused on an innovative approach to produce safer, more effective gene therapies, will present “Use of EVADER AAV8 for repeat dosing in mice and non-human primates” in poster form at ESGCT’s 29th annual conference in Edinburgh, Scotland, U.K.

Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Mark Wiggins as Chief Business Officer and Jakub Simon as Chief Medical Officer.

Elevar Therapeutics, Inc. announced a positive pre-New Drug Application meeting with the U.S. Food and Drug Administration for its investigational drug rivoceranib in combination with camrelizumab as a treatment option for hepatocellular carcinoma, the most common type of liver cancer and cause of more than 830,000 annual deaths worldwide.

Adagene Inc. (“Adagene”) (Nasdaq: ADAG) today announced that it will present clinical data from phase 1b/2 studies of its anti-CTLA-4 antibody candidate, ADG116, at the upcoming Society for Immunotherapy of Cancer’s (SITC) Annual Meeting taking place November 8-12 in Boston.

DICE Therapeutics, Inc. announced that it has commenced an underwritten public offering of $250.0 million of shares of its common stock.

Amylyx Pharmaceuticals, Inc. (“Amylyx”) today announced the closing of its previously announced upsized underwritten public offering of 7,697,812 shares of its common stock at a public offering price of $32.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,004,062 shares of common stock in the offering.

Amarin Corporation plc issued the following statement in response to Sarissa Capital Management LP on behalf of the Amarin Board of Directors.

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS) announced today that the Company will present both an oral and poster at the European Society of Gene and Cell Therapy’s (ESGCT) 29th Congress, to be held in Edinburgh from October 11-14, 2022.

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Sarah Tanksley will join its corporate leadership team as Chief Quality Officer, effective October 14.